Viewing Study NCT05493566


Ignite Creation Date: 2025-12-24 @ 4:39 PM
Ignite Modification Date: 2026-02-01 @ 7:39 PM
Study NCT ID: NCT05493566
Status: RECRUITING
Last Update Posted: 2025-04-01
First Post: 2022-08-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Sponsor: Emory University
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lung Non-Small Cell Carcinoma View
None Stage IV Lung Cancer AJCC V8 View
None Stage IVA Lung Cancer AJCC V8 View
None Stage IVB Lung Cancer AJCC V8 View
Keywords: